Sushil Jain, MD
Internal Medicine · Medina, OHNPI 1538147152
Payments from drug & device makers
Across 145 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$190
- Pfizer$186
- Astellas Pharma US Inc$94
- Xeris Pharmaceuticals, Inc.$84
- E.r. Squibb & Sons, L.L.C.$77
- plus $510 from 19 others
What the payments were for
- Food & beverage$2,440100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 58 | $1,298 |
| Novo Nordisk | 23 | $190 |
| Pfizer | 13 | $186 |
| Astellas Pharma US Inc | 7 | $94 |
| Xeris Pharmaceuticals, Inc. | 4 | $84 |
| E.r. Squibb & Sons, L.L.C. | 5 | $77 |
| Avanir Pharmaceuticals, Inc. | 4 | $65 |
| Merck | 5 | $61 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $44 |
| Exact Sciences | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $37 |
| Sumitomo Pharma America, Inc. | 2 | $33 |
| Hikma Pharmaceuticals USA | 2 | $27 |
| Lilly USA, LLC | 2 | $26 |
| Novartis | 2 | $24 |
| Insmed, Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Melinta Therapeutics, LLC | 1 | $16 |
| AbbVie | 1 | $16 |
| Seqirus USA Inc | 1 | $15 |
| Amgen | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| GSK | 1 | $13 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,440 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 974 | $426,023 |
| FarxigaDapagliflozin Propanediol | 198 | $131,590 |
| XifaxanRifaximin | 36 | $83,770 |
| XareltoRivaroxaban | 115 | $66,223 |
| JanuviaSitagliptin Phosphate | 102 | $61,783 |
| MyrbetriqMirabegron | 172 | $56,136 |
| EntrestoSacubitril/Valsartan | 94 | $54,748 |
| JardianceEmpagliflozin | 61 | $49,882 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $47,055 |
| OzempicSemaglutide | 33 | $30,433 |
| Atorvastatin Calcium | 1,957 | $22,572 |
| Midodrine Hcl | 247 | $21,550 |
| GemtesaVibegron | 43 | $19,645 |
| Potassium Chloride | 942 | $18,507 |
| AranespDarbepoetin Alfa In Polysorbat | 18 | $18,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $186 | $434,8291,002 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Lokelma | $1,298 | $151,690231 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $37 | $83,77036 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $13 | $64,72295 claims |
| MerckJanuvia | $61 | $61,783102 claims |
| Astellas Pharma US IncMyrbetriq | $94 | $56,136172 claims |
| NovartisEntresto | $24 | $54,74894 claims |
| Novo NordiskOzempic | $190 | $30,43333 claims |
| AbbVieVraylar, Linzess | $16 | $24,20849 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $33 | $19,64543 claims |
| AmgenAranesp | $14 | $18,00718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Medina
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
- Narinder SainiSpringfield$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.